EPISODE · May 1, 2018
FX Medicine LIVE Panel from Day 2 of the 6th BioCeuticals Research Symposium
from FX Medicine Podcast Central
In this FX Medicine LIVE Panel at the 6th BioCeuticals Research Symposium in Melbourne, Andrew talks to Robbie Clark, Tammy Guest, Jules Galloway and Keonie Moore about the importance of creating diversity for a thriving business. They also delve into the professional responsibilities that come with moving into the age of tele-medicine. You will be able to find these interviews on the FX Medicine Website under "Industry Insights" https://www.fxmedicine.com.au/industry-insights *****DISCLAIMER: The information provided on FX Medicine is for educational and informational purposes only. The information provided is not, nor is it intended to be, a substitute for professional advice or care. Please seek the advice of a qualified health care professional in the event something you learn here raises questions or concerns regarding your health.*****
What this episode covers
In this FX Medicine LIVE Panel at the 6th BioCeuticals Research Symposium in Melbourne, Andrew talks to Robbie Clark, Tammy Guest, Jules Galloway and Keonie Moore about the importance of creating diversity for a thriving business. They also delve into the professional responsibilities that come with moving into the age of tele-medicine. You will be able to find these interviews on the FX Medicine Website under "Industry Insights" https://www.fxmedicine.com.au/industry-insights *****DISCLAIMER: The information provided on FX Medicine is for educational and informational purposes only. The information provided is not, nor is it intended to be, a substitute for professional advice or care. Please seek the advice of a qualified health care professional in the event something you learn here raises questions or concerns regarding your health.*****
NOW PLAYING
FX Medicine LIVE Panel from Day 2 of the 6th BioCeuticals Research Symposium
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m